John Johnson
Psychiatry · Union City, OHNPI 1720154131
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Alkermes, Inc. at 57.6% of the total. Reporting peaked in 2019 at $50,341 and has fallen 99.2% since, to $402 in 2025. Among psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $430.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$78K
- Axsome Therapeutics, Inc.$43K
- AbbVie$6K
- Sunovion Pharmaceuticals Inc.$5K
- Teva Pharmaceuticals USA, Inc.$504
- Johnson & Johnson$334
- plus $2K from 15 others
What the payments were for
- Consulting fees$35,40626%
- Speaking & faculty fees$79,85459%
- Travel & lodging$12,0429%
- Food & beverage$7,8496%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 83 | $77,900 |
| Axsome Therapeutics, Inc. | 45 | $43,374 |
| AbbVie(2 entities) | 68 | $6,184 |
| Sunovion Pharmaceuticals Inc. | 43 | $5,064 |
| Teva Pharmaceuticals USA, Inc. | 11 | $504 |
| Johnson & Johnson | 9 | $334 |
| Otsuka America Pharmaceutical, Inc. | 21 | $330 |
| E.r. Squibb & Sons, L.L.C. | 9 | $307 |
| Avanir Pharmaceuticals, Inc. | 8 | $206 |
| Jazz Pharmaceuticals Inc. | 2 | $141 |
| Neurocrine Biosciences, Inc. | 2 | $128 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| Lilly USA, LLC | 1 | $122 |
| Harmony Biosciences LLC | 1 | $113 |
| Acadia Pharmaceuticals Inc | 1 | $95 |
| Corcept Therapeutics | 1 | $86 |
| Vanda Pharmaceuticals Inc. | 4 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Braeburn Inc. | 1 | $14 |
| Medline Industries LP | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$307,247
- ARISTADA INITIO$76,812
- Auvelity$42,565
- VRAYLAR$5,280
- LATUDA$4,614
- UZEDY$250
- XYWAV$126
- QUVIVIQ$125
- Austedo XR$124
- INGREZZA$122
- ZEPBOUND$122
- NUEDEXTA$118
- INVEGA SUSTENNA$118
- INVEGA TRINZA$118
- COBENFY$114
- Wakix$113
How this compares
$135,151 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $20,270 |
| VraylarCariprazine Hcl | 11 | $18,057 |
| TrintellixVortioxetine Hydrobromide | 25 | $12,685 |
| Divalproex Sodium ErDivalproex Sodium | 40 | $5,932 |
| Asenapine Maleate | 16 | $5,249 |
| Lurasidone Hcl | 30 | $4,774 |
| Paliperidone ErPaliperidone | 12 | $4,560 |
| Quetiapine Fumarate | 104 | $3,632 |
| Olanzapine | 99 | $3,076 |
| Clozapine | 23 | $2,283 |
| Risperidone | 154 | $2,012 |
| Aripiprazole | 26 | $1,667 |
| Lorazepam | 128 | $1,460 |
| Divalproex Sodium | 38 | $1,413 |
| Haloperidol | 15 | $1,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $206 | $20,27012 claims |
| AbbVieVraylar | $6,184 | $18,05711 claims |
| Lilly USA, LLCOlanzapine | $122 | $3,07699 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Union City
- Henry NasrallahCincinnati$3.8M
- Fred RomeoColumbus$2.3M
- Amita PatelDayton$2.1M
- Pradeep ManudhaneCanton$1.5M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Binit ShahCleveland$913K
- Paul KeckCincinnati$739K
- Ali MelhemSteubenville$681K
- Tracey SkaleCincinnati$674K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.